Aggregation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-16 and is reviewed periodically as new material appears.
After reconstitution, the peptide solution is less stable than the dried powder because water enables hydrolysis, oxidation, and microbial growth. Storage temperature, pH, buffer composition, and container material all affect how long the solution remains usable. Many peptides are kept at 2–8 °C for short-term work, while frozen aliquots at −20 °C or below are used for longer intervals. Repeated freeze-thaw cycles can cause aggregation or precipitation. The choice of storage condition should be based on stability data for the specific peptide.
Quality checks after reconstitution include visual inspection, pH measurement, and analytical methods such as reversed-phase high-performance liquid chromatography. These tests can detect insoluble material, degradation products, and changes in concentration. Mass spectrometry is often used to confirm molecular identity when the peptide sequence is known. Because a clear solution can still contain aggregates or modified peptide, visual clarity alone is not sufficient. Analytical results are compared with a reference standard or the pre-reconstitution certificate of analysis.
Container selection matters because peptides can adsorb to glass, plastic, and filter membranes. Low-binding polypropylene tubes reduce losses for hydrophobic sequences, and filtration through a 0.22 µm membrane can remove particulates and microorganisms. Some peptides may bind to certain filter materials, so compatibility should be checked. Aliquots should be prepared before freezing to avoid repeated temperature cycling. Labels should record the peptide identity, lot number, solvent, concentration, reconstitution date, and storage condition.
Concentration calculations depend on the amount of peptide present in the vial and the volume of solvent added. Lyophilized preparations often contain counterions, salts, or residual water, so the labeled mass may not equal the mass of the peptide itself. This difference can produce a calculated concentration that is higher than the true peptide concentration. Analytical determination of peptide content, rather than reliance on the vial label alone, reduces this source of error. Uncertainty in volume measurement also contributes, especially when small liquid volumes are handled.
Quality records typically include a certificate of analysis, batch number, molecular weight, purity result, and recommended storage conditions. After reconstitution, a laboratory log may record solvent, final volume, date, and storage location. Such documentation supports reproducibility and allows later investigation if a preparation behaves unexpectedly. Stability studies often examine purity and concentration over time under defined temperatures, but results are not universally transferable between peptides or formulations. Open questions remain about how best to predict aggregation for specific sequences and how much analytical testing is sufficient for routine laboratory work.
| Property | Value | Notes |
|---|---|---|
| Lyophilized storage | −20 °C or below | Sealed container with desiccant limits moisture ingress. |
| Reconstituted storage | 2 to 8 °C short term | Freezing aliquots at −20 °C or below may extend stability for some peptides. |
| Preferred container | Low-binding polypropylene | Reduces adsorption losses compared with untreated glass. |
| Sterilization method | 0.22 µm filtration | Filter material compatibility should be verified for each peptide. |
| Common label data | Peptide, lot, date, concentration | Supports traceability and avoids repeated freeze-thaw cycles. |
After reconstitution, peptide solutions are generally less stable than lyophilized powders, and hydrolysis, oxidation, deamidation, and aggregation can occur in solution. Stability depends on peptide sequence, concentration, pH, buffer composition, temperature, light exposure, and dissolved oxygen. Many research protocols store reconstituted solutions at 4 °C for short periods or at -20 °C or -80 °C for longer periods. Repeated freeze-thaw cycles can promote aggregation and loss of activity. The optimal storage condition is peptide-specific and often determined empirically rather than predicted from sequence alone.
Quality control after reconstitution often includes visual inspection for particulates, pH measurement, and concentration determination by ultraviolet absorbance at 280 nm when aromatic residues are present. Reverse-phase high-performance liquid chromatography can assess purity and reveal degradation peaks. Mass spectrometry confirms molecular identity and detects modifications such as oxidation or truncation. Size-exclusion chromatography can quantify aggregates and oligomers. These methods are established for many peptides but may require optimization for hydrophobic or chemically modified sequences.
Microbial contamination is a concern for aqueous peptide solutions, especially those without preservatives. Bacteriostatic water contains an antimicrobial preservative and is used in some laboratory settings, while sterile water lacks preservatives. Filtration through a sterile filter can reduce particulates and microbes, but some peptides adsorb to filter membranes. The effect of preservatives on peptide stability is peptide-dependent and not fully predictable. Documentation of lot number, solvent, date, and storage conditions supports traceability and reproducibility.
Aseptic technique is used when a reconstituted solution must remain free of microbial contamination. Work surfaces, gloves, and instruments are cleaned, and the septum of a vial is disinfected before solvent is added. A venting needle or pressure equalization can prevent aerosol formation and pressure buildup. Bacteriostatic water contains an antimicrobial preservative, but preservatives can interfere with some assays or alter peptide behavior. Sterile filtration may be used when a formulation cannot be heat sterilized or when particulates must be removed.
Quality control for reconstituted peptides includes recording lot number, solvent, date, and storage conditions. Visual inspection checks clarity, color, and particles, while pH measurement verifies the expected solution environment. Concentration is often estimated by ultraviolet absorbance at 280 nm for peptides containing tryptophan or tyrosine, or by high-performance liquid chromatography. Mass spectrometry can confirm molecular identity before reconstitution. Sterility testing is relevant when microbial contamination would invalidate an experiment, though such testing is not routinely performed in every laboratory.
Once a peptide is dissolved, water becomes a medium for hydrolysis, oxidation, and deamidation. Dry powders often tolerate ambient shipping better than liquid solutions, but the exact stability profile depends on sequence and formulation. Refrigerated storage near 2 to 8 degrees Celsius or frozen storage at minus 20 or minus 80 degrees Celsius is common in laboratories. Repeated freeze-thaw cycles can promote aggregation, precipitation, or loss of activity. Dividing a solution into single-use aliquots before freezing can reduce the number of temperature cycles.
==== UK and European Union export ban ==== Due to its use for executions in the US, the UK introduced a ban on the export of sodium thiopental in December 2010, after it was established that no European supplies to the US were being used for any other purpose. The restrictions were based on "the European Union Torture Regulation (including licensing of drugs used in execution by lethal injection)." From December 21, 2011, the European Union extended trade restrictions to prevent the export of certain medicinal products for capital punishment, stating, "The Union disapproves of capital punishment in all circumstances and works towards its universal abolition."
Ciliary neurotrophic factor is a protein that in humans is encoded by the CNTF gene. The protein encoded by this gene is a polypeptide hormone and neurotrophic factor whose actions have mainly been studied in the nervous system where it promotes neurotransmitter synthesis and neurite outgrowth in certain neural populations including astrocytes. It is a hypothalamic neuropeptide that is a potent survival factor for neurons and oligodendrocytes and may be relevant in reducing tissue destruction during inflammatory attacks. A mutation in this gene, which results in aberrant splicing, leads to ciliary neurotrophic factor deficiency, but this phenotype is not causally related to neurologic disease. In addition to the predominant monocistronic transcript originating from this locus, the gene is also cotranscribed with the upstream ZFP91 gene. Cotranscription from the two loci results in a transcript that contains a complete coding region for the zinc finger protein but lacks a complete coding region for ciliary neurotrophic factor. CNTF has also been shown to be expressed by cells on the bone surface, and to reduce the activity of bone-forming cells (osteoblasts).
=== Drug–drug interactions with siRNA therapeutics === As the number of approved RNAi therapeutics has grown, reaching seven in 2025 (patisiran, givosiran, lumasiran, inclisiran, vutrisiran, nedosiran, and fitusiran), a distinct challenge has emerged in assessing drug–drug interactions (DDIs) for this drug class. Unlike small-molecule drugs, siRNA therapeutics are not major substrates of cytochrome P450 enzymes and do not rely on classical hepatic or renal uptake transporters. Instead, they are metabolized by endogenous endo- and exonucleases to shortened oligonucleotide chains, and their systemic pharmacokinetic parameters often do not reflect target-tissue distribution or pharmacodynamic (PD) outcomes. A clinically observed example of an unexpected DDI is givosiran, which produced a 2- to 3-fold increase in systemic exposure to cytochrome P450 substrates dextromethorphan (CYP2D6) and caffeine (CYP1A2) in patients with acute intermittent porphyria—an effect not predicted by standard in vitro CYP enzyme studies. The proposed mechanism involves indirect interference with hepatic heme biosynthesis via on-target suppression of aminolevulinate synthase 1 (ALAS1), rather than direct enzyme inhibition. More broadly, siRNA drugs may compete with endogenous microRNAs (miRNAs) for shared components of the RNA-induced silencing complex (RISC), particularly Argonaute (AGO) proteins.
=== Facilitates the quaternary structure === The enzyme cytochrome c oxidase, also known as Complex IV, is a large transmembrane protein complex found in mitochondria and bacteria. It is the last enzyme in the respiratory electron transport chain located in the inner mitochondrial or bacterial membrane. It receives an electron from each of four cytochrome c molecules, and transfers them to one oxygen molecule, converting molecular oxygen to two molecules of water. Complex IV has been shown to require two associated CL molecules in order to maintain its full enzymatic function. Cytochrome bc1 (Complex III) also needs cardiolipin to maintain its quaternary structure and functional role. Complex V of the oxidative phosphorylation machinery also displays high binding affinity for CL, binding four molecules of CL per molecule of complex V.
Sources: en.wikipedia.org
== Origin == The Kalyāṇakāraka, composed in South India by Ugrāditya, is the earliest medical work to contain alchemical content. It is datable to the early ninth century CE. It gives descriptions for the processing of mercury and uses technical terminology related to the procedures and implements required for alchemy. It is the first work to describe purifying (śodhana) and calcining (māraṇaʼ) mercury for medicinal use. The first work of the Sanskrit alchemical literary genre called rasaśāstra is the 10th century Rasahṛdayatantra. The texts 19 chapters focus on the processing mercury, outlines 18 means to process mercury and discusses the transmutation of metals and the body.
== Selected publications == Balalaie, S.; Hashtroudi, M. S.; Arabanian, A. (2000). "One-pot synthesis of tetrasubstituted imidazoles catalyzed by zeolite HY and silica gel under microwave irradiation". Green Chemistry. 2 (6): 274–276. doi:10.1039/b006201o. Balalaie, S.; Bararjanian, M.; Amani, A. M.; Movassagh, B. (2006). "(S)-Proline as a neutral and efficient catalyst for the one-pot synthesis of tetrahydrobenzo [b] pyran derivatives in aqueous media". Synlett. 2006 (2): 263–266. doi:10.1055/s-2005-923606. Bararjanian, M.; Balalaie, S.; Rominger, F.; Movassagh, B.; Bijanzadeh, H. R. (2010). "Six-component reactions for the stereoselective synthesis of 3-arylidene-2-oxindoles via sequential one-pot Ugi/Heck carbocyclization/Sonogashira/nucleophilic addition". The Journal of Organic Chemistry. 75 (9): 2806–2812. doi:10.1021/jo902713x. PMID 20387848. Balalaie, S.; Bararjanian, M.; Hosseini, M.S.; Bigdeli, Z. (2006). "One-pot synthesis of 1,4-dihydropyridine derivatives in a solvent-free condition". Helvetica Chimica Acta. 89 (8): 1769–1773. doi:10.1002/hlca.200690161. Balalaie, S.; Sharafi-Kolkesh, A. (2003). "A novel and efficient one-pot synthesis of 2,4,6-triarylpyridines under solvent-free conditions". Zeitschrift für Naturforschung B. 58 (10): 1075–1077. doi:10.1515/znb-2003-1021.
=== Suicide === The US Food and Drug Administration (FDA) requires all antidepressants, including sertraline, to carry a boxed warning stating that antidepressants increase the risk of suicide in persons younger than 25 years. This warning is based on statistical analyses conducted by two independent groups of FDA experts that found a 100% increase of suicidal thoughts and behavior in children and adolescents, and a 50% increase in the 18–24 age group. Suicidal ideation and behavior in clinical trials are rare. For the above analysis, the FDA combined the results of 295 trials of 11 antidepressants for psychiatric indications to obtain statistically significant results. Considered separately, sertraline use in adults decreased the odds of suicidal behavior with a marginal statistical significance of 37% or 50% depending on the statistical technique used. The authors of the FDA analysis note that "given the large number of comparisons made in this review, chance is a very plausible explanation for this difference". The more complete data submitted later by the sertraline manufacturer Pfizer indicated increased suicidal behavior. Similarly, the analysis conducted by the UK MHRA found a 50% increase of odds of suicide-related events, not reaching statistical significance, in the patients on sertraline as compared to the ones on placebo.
Sources: en.wikipedia.org
== Etymology == The genus Naegleria was established by Alexis Alexeieff in 1912, who grouped the flagellate amoeba. He coined the term Naegleria after Kurt Nägler, who researched amoebae. The species was named after Malcolm Fowler, an Australian pathologist at Adelaide Children's Hospital, who was the first author of the original series of case reports (British Medical Journal, starting 1965) of PAM.
==== Nucleic acid and cell-binding peptide biosensors ==== Peptides can also be engineered to recognize and bind DNA, RNA or specific cell types. Peptides that bind nucleic acid may contain cationic or helix-forming motifs that promoite selective interaction, cell-binding peptides oftentimes mimic natural ligand sequences (e.g RGD peptides binding integrins). These biosensors, which provide great selectivity while preserving structural stability, are employed in pathogen detection, cancer diagnostics, and cell profiling.
Solved structures are usually deposited in the Protein Data Bank (PDB), a freely available resource from which structural data about thousands of proteins can be obtained in the form of Cartesian coordinates for each atom in the protein. Many more gene sequences are known than protein structures. Further, the set of solved structures is biased toward proteins that can be easily subjected to the conditions required in X-ray crystallography, one of the major structure determination methods. In particular, globular proteins are comparatively easy to crystallize in preparation for X-ray crystallography. Membrane proteins and large protein complexes, by contrast, are difficult to crystallize and are underrepresented in the PDB. Structural genomics initiatives have attempted to remedy these deficiencies by systematically solving representative structures of major fold classes. Protein structure prediction methods attempt to provide a means of generating a plausible structure for proteins whose structures have not been experimentally determined.
== History == Cranio-lenticulo-sutural dysplasia was first discovered by Simeon Boyadjiev Boyd, chief of the Section of Genetics at UC Davis Children's Hospital, in 2003. CLSD was found a consanguineous (sharing a common ancestor) Saudi Arabian family of Bedouin descent. The children who were affected inherited the defective gene from both of their parents (Boyadjiev, 1193). A Caucasian male was also found to have symptoms of the disease, but possessed only one defective chromosome. Measurements of the endoplasmic reticulums of his mother and father showed that the mother had a normal phenotype, the father had a slightly distended endoplasmic reticulum, and the affected son had an endoplasmic reticulum distended to a much greater extent. Because of the normal measurements obtained from the mother, it was concluded that the father was responsible for the son's symptoms and was hypothesized that there was another mutation on chromosome 14 that caused the disease to manifest itself without a secondary disease carrying chromosome he would have inherited from his mother. It is associated with a mutation changing the translation of phenylalanine to leucine in SEC23A.
Sources: en.wikipedia.org
Short-term storage is often at 2 to 8 °C, while longer storage may use frozen aliquots at −20 °C or below. Repeated freeze-thaw cycles should be avoided because they can promote aggregation.
Cloudiness may indicate incomplete dissolution, aggregation, or precipitation. Gentle mixing, pH adjustment, or filtration can sometimes resolve it, but the cause should be identified before use.
Bacteriostatic water contains a preservative that can interfere with some assays or react with certain peptides. Sterile water or a defined buffer may be preferable depending on the downstream application.
Ultraviolet absorbance is common when the peptide's extinction coefficient is known. Reverse-phase HPLC with calibration standards can also estimate concentration. Amino acid analysis or quantitative mass spectrometry may be used when higher accuracy is needed.